These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 9076812)

  • 41. Carbapenems and monobactams: imipenem, meropenem, and aztreonam.
    Hellinger WC; Brewer NS
    Mayo Clin Proc; 1999 Apr; 74(4):420-34. PubMed ID: 10221472
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antibacterial properties of meropenem towards clinical isolates, beta-lactamase producers and laboratory mutants.
    Wiedemann B; Zühlsdorf M
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():197-205. PubMed ID: 2681124
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Antibiotic susceptibility of isolates from blood of patients in intensive care units of emergency medical service].
    Chernen'kaia TV; Borisova LA; Vorob'eva TIu; Aleksandrova IV; Kosolapov DA
    Antibiot Khimioter; 2011; 56(5-6):30-6. PubMed ID: 22145228
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bacteriostatic and bactericidal in-vitro activity of meropenem against clinical isolates, including Mycobacterium avium complex.
    Inderlied CB; Lancero MG; Young LS
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():85-99. PubMed ID: 2808217
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance.
    Jones RN; Kirby JT; Rhomberg PR
    Diagn Microbiol Infect Dis; 2008 Jun; 61(2):203-13. PubMed ID: 18329835
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of Meropenem for Use in Bacterial Keratitis.
    Sueke H; Kaye S; Wilkinson MC; Kennedy S; Kearns V; Zheng Y; Roberts P; Tuft S; Neal T
    Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5731-8. PubMed ID: 26325409
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Meropenem: an updated review of its use in the management of intra-abdominal infections.
    Lowe MN; Lamb HM
    Drugs; 2000 Sep; 60(3):619-46. PubMed ID: 11030471
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study.
    Joly-Guillou ML; Kempf M; Cavallo JD; Chomarat M; Dubreuil L; Maugein J; Muller-Serieys C; Roussel-Delvallez M
    BMC Infect Dis; 2010 Mar; 10():72. PubMed ID: 20298555
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Trends in paediatric and adult bloodstream infections at a Ghanaian referral hospital: a retrospective study.
    Obeng-Nkrumah N; Labi AK; Addison NO; Labi JE; Awuah-Mensah G
    Ann Clin Microbiol Antimicrob; 2016 Aug; 15(1):49. PubMed ID: 27539221
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Pharmacokinetic and clinical studies with meropenem in the pediatric field. Pediatric Study Group of Meropenem].
    Fujii R; Yoshioka H; Fujita K; Maruyama S; Sakata H; Inyaku F; Chiba S; Tsutsumi H; Wagatsuma Y; Fukushima N
    Jpn J Antibiot; 1992 Jun; 45(6):697-717. PubMed ID: 1507401
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical significance of cerebrospinal fluid inhibitory titers of antibiotics, based on pharmacokinetic/pharmacodynamic parameters, in the treatment of bacterial meningitis.
    Morikawa Y; Kitazato M; Morita T; Mizunaga S; Mitsuyama J
    J Infect Chemother; 2009 Aug; 15(4):233-8. PubMed ID: 19688242
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates.
    Turner PJ
    Diagn Microbiol Infect Dis; 2009 Feb; 63(2):217-22. PubMed ID: 19070453
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety profile of meropenem: an updated review of over 6,000 patients treated with meropenem.
    Linden P
    Drug Saf; 2007; 30(8):657-68. PubMed ID: 17696578
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from Europe: comparison of antibiotic susceptibilities between countries and centre types. MYSTIC Study Group (European centres only).
    Goossens H
    J Antimicrob Chemother; 2000 Sep; 46 Suppl T2():39-52. PubMed ID: 11065147
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Susceptibility of anaerobic bacteria to meropenem.
    Nord CE; Lindmark A; Persson I
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():113-7. PubMed ID: 2553656
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Meropenem, a new carbapenem antibiotic.
    Fish DN; Singletary TJ
    Pharmacotherapy; 1997; 17(4):644-69. PubMed ID: 9250544
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Meropenem stability to beta-lactamase hydrolysis and comparative in vitro activity against several beta-lactamase-producing Gram-negative strains.
    Franceschini N; Segatore B; Perilli M; Vessillier S; Franchino L; Amicosante G
    J Antimicrob Chemother; 2002 Feb; 49(2):395-8. PubMed ID: 11815587
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antibiotic resistance surveillance over a 4-year period (2000-2003) in Turkey: results of the MYSTIC Program.
    Korten V; Ulusoy S; Zarakolu P; Mete B;
    Diagn Microbiol Infect Dis; 2007 Dec; 59(4):453-7. PubMed ID: 17888609
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In-vitro studies of meropenem.
    Jones RN; Barry AL; Thornsberry C
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():9-29. PubMed ID: 2808218
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Meropenem].
    Escolar M; Honorato J
    Rev Med Univ Navarra; 1995; 39(4):42-7. PubMed ID: 9499841
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.